| Route |
Dose Level (mmol/kg) |
C0a (µg/mL)
(Cmax for po) |
tmax (h) |
AUCb (h•µg/mL) |
Cl (mL/h/kg)c |
V (L/kg)c |
t½ (h) |
Fd(%) |
| 5-LIO(Me-3,2-HOPO) |
| iv |
100 |
197 ± 6 |
NAe |
107 ± 9 |
383 ± 30 |
0.42 ± 0.06 |
0.77 ± 0.06 |
NA |
| po |
150 |
7.12 ± 4.90 |
0.50 ± 0.00 |
8.27 ± 5.41 |
380 ± 1 |
0.47 ± 0.11 |
0.85 ± 0.21 |
5.15 ± 3.38 |
| po |
500 |
9.07 ± 7.98 |
0.83 ± 0.29 |
17.0 ± 16.4 |
381 ± 2 |
1.00 ± 0.12 |
1.83 ± 0.23 |
3.19 ± 3.07 |
| 3,4,3-LI(1,2-HOPO) |
| iv |
30 |
144 ± 27 |
NA |
47 ± 6 |
481 ± 63 |
1.60 ± 0.23 |
2.33 ± 0.44 |
NA |
| po |
100 |
NDf |
ND |
ND |
ND |
ND |
ND |
ND |
| po |
500 |
1.77 ± 0.64 |
1.25 ± 1.52 |
3.79 ± 1.03 |
479 ± 3 |
0.78 ± 0.46 |
1.13 ± 0.66 |
0.48 ± 0.13 |
aC0 is the plasma concentration extrapolated to time zero.
bAUC presented is extrapolated to infinity.
cFor po administrations, V and Cl were calculated from V/F•F and Cl/F•F, respectively.
dThe bioavailability F is expressed as a percentage.
eNA = not applicable.
fND = no data, the test article was not detected. |
